Geninus Presents Preclinical Data of Anti-Cancer Vaccine at US SITC

Geninus, a genome analysis specialist company (CEO Park Woong-yang), announced on the 4th that it will present preclinical efficacy test data at the Society for Immunotherapy of Cancer 2023 (SITC 2023), held in San Diego starting November 1.

SITC, established in 1984, is the most prestigious society in the field of immuno-oncology, with over 4,600 scientists, researchers, and clinicians from 63 countries worldwide engaged in cancer research and treatment as members. It holds an annual academic conference to develop and advance immunotherapy methods with the common goal of treating cancer patients.

The research topic Geninus will present at this SITC is "Induction of Clonal Expansion of Tumor-Reactive T Cells through Neoantigens Predicted by the VACINUS Platform."

Following last year's presentation of immune response experimental results of the anticancer vaccine platform VACINUS at SITC, this year the company will additionally disclose preclinical efficacy data.

Song Kyu-young, head of Geninus New Drug Development Research Center, said, "We are pleased to be able to additionally present preclinical data verifying Geninus's neoantigen prediction strategy in animal models at SITC, which holds global authority in the immuno-oncology field," and added, "We hope to further present research results conducted during the clinical trial preparation stage next time."

Meanwhile, Geninus's abstract will be available on the SITC website from October 31 local time, and the company plans to submit an IND (Investigational New Drug application) for Phase 1 clinical trials within next year.